0.2917

12.84% 0.0332

After Hours: .28 -0.0117 -4.01%

Genprex Inc (GNPX)

Overview News Price History Option Chain Financials Discussions Forecast

Genprex Inc stock is traded at $0.2917, with a volume of 12.08M. It is up +12.84% in the last 24 hours and up +24.39% over the past month. Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Previous Close:

$0.2585

Open:

$0.2558

24h Volume:

12.08M

Relative Volume:

1.39

Market Cap:

$9.76M

Revenue:

Net Income/Loss:

$-22.71M

P/E Ratio:

-0.0249

EPS:

-11.71

Net Cash Flow:

$-18.24M

1W Performance:

+27.10%

1M Performance:

+24.39%

6M Performance:

-15.45%

1Y Performance:

-32.16%

1-Day Range:

$0.2482

$0.3189

1-Week Range:

$0.20

$0.4045

52-Week Range:

$0.14

$3.97

Genprex Inc Stock (GNPX) Company Profile

Name

Genprex Inc

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

512-537-7997

Address

1601 TRINITY STREET, BLDG. B, AUSTIN, TX

Employee

Twitter

@genprex

Next Earnings Date

2024-11-12

Latest SEC Filings

GNPX's Discussions on Twitter

Compare GNPX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GNPX Genprex Inc	0.2917	8.37M	0	-22.71M	-18.24M	-11.71
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Genprex Inc Stock (GNPX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-21	Initiated	National Securities	Buy
Apr-29-19	Initiated	Noble Capital Markets	Outperform

Genprex Inc (GNPX)

Genprex Inc Stock (GNPX) Company Profile

Compare GNPX with other stocks

Genprex Inc Stock (GNPX) Upgrades & Downgrades

Genprex Inc Stock (GNPX) Latest News

Will Genprex Inc. continue its uptrendTrade Signal Summary & Real-Time Stock Price Movement Reports - Newser

Identifying reversal signals in Genprex Inc.Trade Analysis Summary & Stepwise Trade Signal Guides - Newser

Genprex (GNPX) Files to Sell 25 Million Common Shares - GuruFocus

Quantitative breakdown of Genprex Inc. recent move2025 Investor Takeaways & Weekly Consistent Profit Watchlists - Newser

What machine learning models say about Genprex Inc.Quarterly Profit Review & Target Return Focused Stock Picks - Newser

Institutional scanner results for Genprex Inc.July 2025 Weekly Recap & Stock Portfolio Risk Control - Newser

Short interest data insights for Genprex Inc.Trade Exit Summary & Weekly Breakout Stock Alerts - Newser

Ranking Genprex Inc. among high performing stocks via toolsPortfolio Return Summary & Short-Term Trading Alerts - Newser

Using R and stats models for Genprex Inc. forecastingWeekly Market Report & Daily Technical Forecast Reports - Newser

How to escape a deep drawdown in Genprex Inc.Earnings Trend Report & Daily Technical Forecast Reports - Newser

Genprex Inc.’s volatility index tracking explainedInsider Selling & Verified Entry Point Signals - Newser

What earnings revisions data tells us about Genprex Inc.Options Play & Real-Time Volume Trigger Notifications - Newser

Using AI based signals to follow Genprex Inc.Weekly Profit Analysis & Weekly Chart Analysis and Trade Guides - Newser

Genprex Inc. stock daily chart insightsJuly 2025 Update & Breakout Confirmation Trade Signals - Newser

Custom watchlist performance reports with Genprex Inc.Global Markets & Stepwise Trade Execution Plans - Newser

Using Ichimoku Cloud for Genprex Inc. technicals2025 Historical Comparison & AI Enhanced Trading Signals - Newser

How to use Fibonacci retracement on Genprex Inc.2025 Institutional Moves & Weekly Watchlist for Hot Stocks - Newser

Will earnings trigger a reversal in Genprex Inc.Market Activity Summary & Consistent Income Trade Recommendations - Newser

Statistical indicators supporting Genprex Inc.’s strengthDay Trade & Weekly Return Optimization Plans - Newser

Genprex Inc. stock volume spike explainedJuly 2025 Gainers & Weekly High Return Forecasts - Newser

Genprex Inc. stock chart pattern explained2025 Volatility Report & AI Powered Buy/Sell Recommendations - Newser

Has Genprex Inc. formed a bullish divergenceTrade Signal Summary & Smart Swing Trading Alerts - Newser

Genprex Is Betting On Gene Therapy, But Risks Remain High - Finimize

will genprex inc. continue its uptrendRate Cut & Real-Time Volume Trigger Notifications - Newser

Ryan Confer, President and Chief Executive Officer of Genprex, Inc., to Present at Investor Summit Virtual on September 16, 2025 - FinancialContent

Genprex Inc. stock trend forecast2025 Biggest Moves & Low Risk High Win Rate Picks - Newser

Chartists Watching For Breakout in Genprex Inc.Earnings Risk Summary & Community Consensus Picks - Newser

Is Genprex Inc. stock undervalued right nowJuly 2025 Fed Impact & Stock Market Timing Techniques - Lancaster City Council

Will Genprex Inc. outperform tech stocks2025 EndofYear Setup & Expert Approved Trade Ideas - Lancaster City Council

Genprex Inc Stock (GNPX) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to GNPX